Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

Dundee University scientists in world-leading development of drug to break ‘vicious cycle’ of long-term lung condition

Post Thumbnail

Dundee University scientists are at the forefront of a world-leading project  to create a new drug which could dramatically improve the lives of thousands of chronic lung condition sufferers.

The final results of a major international study were announced by a leading city academic to a virtual meeting of the American Thoracic Society broadcast around the globe.

James Chalmers, British Lung Foundation Professor of Respiratory Research at Dundee University said the second phase of the Willow scheme had delivered clinical trial results which could see the drug become reality for people living with long-term lung conditions.

Professor James Chalmers.

It could prevent the need for antibiotics or emergency surgery, transforming the lives of 200,000 people UK-wide affected by a condition which claims 1,500 lives each year.

Scientists at the university, in collaboration with global biopharmaceutical company Insmed Incorporated, tested brensocatib in patients living with non-cystic fibrosis bronchiectasis, a build-up of mucus which causes abnormal widening of the airways.

Finals results showed patients could potentially reduce their risk of pulmonary disease caused by the condition by more than a third.

The university’s school of medicine is currently exploring whether brensocatib could also be used to prevent the need for mechanical ventilation in Covid-19 cases.

The drug will need to undergo further rounds of clinical trials and receive regulatory approval before it can be routinely prescribed by doctors.

Professor Chalmers said: “Living with bronchiectasis means that you’re constantly at risk of needing emergency treatment when the condition worsens.

“We currently rely on antibiotics to treat the chest infections caused by bronchiectasis, with few options to stop the disease from getting worse in the first place.

“We are excited by the possibility of a drug which can break the vicious cycle of inflammation, lung damage and infection for these patients, giving them a much better quality of life.

“This trial is a world first in treating an incurable lung condition that affects millions of people worldwide.”

Although many cases of bronchiectasis are normally treated with a short course of antibiotics, hospital treatment is often the required to deal with more serious instances.

Symptoms include chronic cough, excessive sputum production, shortness of breath, and repeated chest infections, which can worsen the underlying condition.